Recursion Pharmaceuticals Q4 2023 GAAP EPS $(0.42) Beats $(0.44) Estimate, Sales $10.89M Miss $20.35M Estimate

Author: Benzinga Newsdesk | February 27, 2024 05:37pm
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.44) by 4.55 percent. This is a 35.48 percent decrease over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $10.89 million which missed the analyst consensus estimate of $20.35 million by 46.49 percent. This is a 20.36 percent decrease over sales of $13.68 million the same period last year.

Posted In: RXRX